CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

high-titer anti-Sars-CoV-2 plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1365 oxygen therapy Wiki 0.71

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D017563 Lung Diseases, Interstitial NIH 0.45
D011014 Pneumonia NIH 0.07

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0006515 Interstitial pneumonitis HPO 0.45
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19

Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.

NCT04333251 Pneumonia, Interstitial Biological: high-titer anti-Sars-CoV-2 plasma Other: oxygen therapy
MeSH:Pneumonia Lung Diseases, Interstitial
HPO:Interstitial pneumonitis Interstitial pulmonary abnormality Pneumonia

Primary Outcomes

Description: reduction in oxygen and ventilation support

Measure: reduction in oxygen and ventilation support

Time: through study completion, an average of 4 weeks

Related HPO nodes (Using clinical trials)